3V Medical Research Group Luxol™ & Ostrolux™ Study Data
Comparing the In vitro effects on COVID virus of Luxol™ (3VM1000) and remdesivir – 3VM1000 has a clearly demonstrable killing effect against the COVID virus.
In a study (3VM0115) of Ostrolux™ in patients with osteoarthritis of the knee, Ostrolux™ showed superior efficacy compared to placebo, in the per protocol population (n=36 of 48total)
VAS Scores improved with Ostrolux™ at days 7 and 30
Patient rating of disease severity also improved with Ostrolux™ treatment
Side effects seen were rare and mild.
In summary, safety and effectiveness results seem promising for Ostrolux™. But several more larger scale studies will be required to demonstrate if these results are valid.